NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +14 vs. previous quarter
- 47
- 13F valueReported value at the end of Q2 2026
- $47.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NRXP, Q2 2026
No superinvestor reported holding NRXP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by NRX Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 (view filing) | Dec 17 | 1 day | Javitt Jonathan CChairman and Chief Scientist | PPurchase | +40.0K | $1.17 | +$46.8K | +89.6%84.6K after | |
| Sep 11, 2023 (view filing)9:19 AM ET | Aug 30 | 12 daysLate | Gorovitz AaronDirector | PPurchaseCommon Stock, par value $0.001 per share | +35.0K | $0.3199 | +$11.2K | +50.0%105.0K after | |
| Sep 11, 2023 (view filing)9:15 AM ET | Aug 30 | 12 daysLate | Hurvitz ChaimDirector | PPurchaseCommon Stock, par value $0.001 per share | +70.0K | $0.2875 | +$20.1K | +14.0%570.0K after | |
| Aug 24, 2023 (view filing)12:14 PM ET | Aug 23 | 1 day | Javitt Jonathan CChief Scientist | PPurchase | +100.0K | $0.33 | +$33.0K | +28.9%446.3K after | |
| Aug 23, 2023 (view filing)9:24 AM ET | Aug 22 | 1 day | Javitt Jonathan CChief Scientist | PPurchase | +200.0K | $0.322 | +$64.4K | +136.7%346.3K after | |
| Dec 19, 2022 (view filing) | Dec 16 | 3 days | Willard Stephen HCHIEF EXECUTIVE OFFICER | PPurchaseCommon Stock, par value $0.001 per share | +50.0K | $1.17 | +$58.5K | New position50.0K after | |
| Dec 19, 2022 (view filing) | Dec 16 | 3 days | Van Voorhees SethCHIEF FINANCIAL OFFICER | PPurchaseCommon Stock, par value $0.001 per share | +30.0K | $1.10 | +$33.0K | +183.6%46.3K after | |
| Dec 19, 2022 (view filing) | Nov 25 | 24 days | Van Voorhees SethCHIEF FINANCIAL OFFICER | PPurchaseCommon Stock, par value $0.001 per share | +16.3K | $1.11 | +$18.2K | New position16.3K after | Amended3 lots |
| Dec 9, 2022 (view filing) | Dec 7 | 2 days | Javitt Jonathan CDirector, 10% Owner | SSaleCommon Stock, par value $0.001 per share | −400.0K | $1.00 | −$400.0K | −3.0%12.9M after | |
| Dec 1, 2022 (view filing) | Nov 29-30 | 2 days | Javitt Daniel C.10% Owner | SSale | −22.2K | $1.50 | −$33.3K | −0.2%9.63M after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in NRX Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| B Group, Inc. | 4,091,767 | $16.7M | 9.50% | +1,091,767+36.4% | Added |
| Vanguard Capital Management LLC | 1,618,159 | $6.62M | 0.00% | +457,975+39.5% | Added |
| Ameriprise Financial Inc | 928,728 | $3.80M | 0.00% | +928,728 | New |
| Balyasny Asset Management LLC | 893,864 | $3.66M | 0.01% | +893,864 | New |
| Citadel Advisors LLC | 680,043 | $2.78M | 0.00% | +680,043 | New |
| AdvisorShares Investments LLC | 659,018 | $2.70M | 0.33% | +238,551+56.7% | Added |
| Commonwealth Equity Services, LLC | 454,418 | $1.86M | 0.00% | +56,987+14.3% | Added |
| UBS Group AG | 423,115 | $1.73M | 0.00% | +397,888+1,577.2% | Added |
| Geode Capital Management, LLC | 314,659 | $1.29M | 0.00% | +4,547+1.5% | Added |
| BlackRock, Inc. | 220,460 | $901.7K | 0.00% | +121,465+122.7% | Added |